NCT05840510View on ClinicalTrials.gov

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
Solid Tumor, AdultNSCLCAdvanced CancerMetastatic CancerMalignant Neoplastic Disease
Interventions
DRUG

Adagrasib

KRAS G12C inhibitor

DRUG

nab-Sirolimus

mTOR inhibitor

Trial Locations (3)

37203

Local Institution - 019-101, Nashville

44121

Local Institution - 019-104, Cleveland

77030-4000

Local Institution - 019-102, Houston

Sponsors

Collaborators (1)

Aadi Bioscience, Inc.
All Listed Sponsors
collaborator

Aadi Bioscience, Inc.

INDUSTRY

lead

Mirati Therapeutics Inc.

INDUSTRY

NCT05840510 - Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | Biotech Hunter | Biotech Hunter